MIG Capital AG

Jürgen Kosch is a cofounder and Managing Partner at MIG Capital AG and serves as Chairman of the Advisory Board (Beiratsvorsitzender) of lxp Group. His background includes venture capital investment management in technology companies, angel investing, and founding multiple companies.

Partner at MIG since 2022 focused on life sciences and high-growth companies, supporting founders and management on strategic management and operational excellence. His background spans management consulting, leading biotech companies, and founding his own business. He holds a BS in business administration from Syracuse University and an MBA from Bocconi University.

Fei Tian joined MIG's investment team in April 2023, strengthening the Life Science division. She previously managed the health tech portfolio at yabeo Venture Tech and spent nine years at Vesalius Biocapital as an investment analyst and later principal. She studied medicine at Tongji University in China, worked as an emergency physician, and earned a doctorate in oncology and stem cell research at Ludwig-Maximilians-Universität.

Fei Tian joined MIG's investment team in April 2023, working in the firm's life science area with a focus on healthcare. She previously managed the health tech portfolio at yabeo Venture Tech and spent nine years at Vesalius Biocapital, rising from investment analyst to principal, where she worked on deal identification, due diligence, and transaction structuring in life-science investments. She studied medicine at Tongji University in China, worked two years as an emergency physician, and earned a doctorate in oncology and stem cell research at Ludwig Maximilian University.

Frederick Michna joined MIG's investment team in June 2022, bringing experience from both startups and corporations. He previously spent over six years at consultancy Kearney leading transformation and growth programs in finance, telecom and aviation, and earlier worked on financing and incubating digital business models at Swiss VC Mountain Partners. He holds a Master's in Strategic Management from HEC Paris and a Bachelor's in International Management from ESB Reutlingen and Reims Management School.

Business development team member focused on bio, working on the Collective Fund.

Valérie Calenda is a Managing Partner at Mérieux Equity Partners, which she joined as Partner in January 2010, focusing on venture deal flow and investments and supporting more than ten companies in Europe and North America. She began her career as a research scientist in hematology and virology at Inserm before joining Transgene S.A., where she managed programs in HIV, cardiovascular disease, and oncology, advanced product candidates to clinical stage, and contributed to license agreements including a 2007 agreement with Hoffmann-La Roche on the HPV cancer vaccine candidate TG4001. She holds a PhD in pharmacology, a degree in hematology, and a B.Sc. in biochemistry-immunology from the University of Marseille, and serves on the boards of companies including Amyl Therapeutics, Keranova, AcuSurgical, Deepull, Biophta, and Prodigest.

Christina Vogt-Sasse is a Senior Associate at MIG Capital in Munich, where she invests in deeptech companies across aerospace, future of compute, and energy. She has a background in aerospace engineering and strategy consulting and is building a venture called Ventra.

Leads finance, operations, fund modeling, follow-on investing, and LP relations. He joined full-time in 2021 after serving as outsourced CFO through Airstream Alpha, which he founded in 2018, and previously spent a decade as an institutional LP leading PE/VC investing at Texas Children's Hospital's foundation.